The tumor innate immune microenvironment in prostate cancer: an overview of soluble factors and cellular effectors.
Maria Teresa PalanoMatteo GallazziMartina CucchiaraFederico DehòPaolo CapogrossoAntonino BrunoLorenzo MortaraPublished in: Exploration of targeted anti-tumor therapy (2022)
Prostate cancer (PCa) accounts as the most common non-cutaneous disease affecting males, and as the first cancer, for incidence, in male. With the introduction of the concept of immunoscore, PCa has been classified as a cold tumor, thus driving the attention in the development of strategies aimed at blocking the infiltration/activation of immunosuppressive cells, while favoring the infiltration/activation of anti-tumor immune cells. Even if immunotherapy has revolutionized the approaches to cancer therapy, there is still a window failure, due to the immune cell plasticity within PCa, that can acquire pro-tumor features, subsequent to the tumor microenvironment (TME) capability to polarize them. This review discussed selected relevant soluble factors [transforming growth factor-beta (TGFβ), interleukin-6 (IL-6), IL-10, IL-23] and cellular components of the innate immunity, as drivers of tumor progression, immunosuppression, and angiogenesis within the PCa-TME.
Keyphrases
- prostate cancer
- transforming growth factor
- cancer therapy
- radical prostatectomy
- innate immune
- epithelial mesenchymal transition
- induced apoptosis
- stem cells
- papillary thyroid
- poor prognosis
- drug delivery
- endothelial cells
- working memory
- signaling pathway
- endoplasmic reticulum stress
- vascular endothelial growth factor
- anti inflammatory
- cell proliferation
- lymph node metastasis
- wound healing
- pi k akt